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 Nonalcoholic fatty liver disease (NAFLD) is the most 
common chronic liver disease in the Western world ( 1 ). It 
is estimated to affect 10–50% of the population ( 2 ). The 
disease presents primarily as steatosis contributing to met-
abolic alterations such as insulin resistance, hyperglyce-
mia, and hyperlipidemia ( 3–5 ). However, NAFLD can also 
lead to nonalcoholic steatohepatitis (NASH) with a poten-
tial of leading to liver cirrhosis and liver failure ( 6 ). 
 Increased triglyceride synthesis and accumulation are 
characteristic in a steatotic liver ( 7 ). In addition, choles-
terol synthesis is also increased in NAFLD ( 8 ), and choles-
terol accumulation has been suggested to contribute to 
liver cell injury in NASH ( 9 ). The related overproduction 
of VLDL particles in the metabolic syndrome ( 10 ) and 
NAFLD ( 4 ) has been thought to be a consequence of this 
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was calculated by subtracting the LDL, IDL, and HDL cholesterol 
from the total cholesterol. The total cholesterol content of chylo-
microns and extremely large VLDL, very large VLDL and very 
small VLDL was calculated by subtracting the triglyceride and 
phospholipid concentrations from the total lipids of each sub-
class. Lipid composition as a percentage of each available lipid 
of the total lipid content in each lipoprotein subclass was also 
calculated. 
 Liver histology 
 Liver biopsies were obtained using a Tru-Cut needle (Ra-
diplast AB, Uppsala, Sweden) during elective gastric bypass op-
erations. Overall histological assessment of liver biopsy samples 
was performed by one pathologist according to the standard cri-
teria ( 23, 24 ), and histological diagnosis was divided into three 
categories:  1 ) normal liver without any steatosis, infl ammation, 
ballooning, or fi brosis;  2 ) simple steatosis (steatosis >5%) with-
out evidence of hepatocellular ballooning, infl ammation, or fi -
brosis; and  3 ) NASH (supplementary Tables I, II). When 
analyzing the effects of the gastric bypass operation, a different 
histological characterization was used to separate normal from 
probable and defi nite NASH (supplementary Table III): steatosis 
was graded into four categories (<5, 5–33, 33–66, and >66%); 
lobular infl ammation was graded into four categories (no foci, 
<2, 2–4, and >4 per 200× fi eld); fi brosis was staged from 1 to 4 
and ballooning from 0 to 2. When all four variables were present, 
the diagnosis was “defi nite steatohepatitis,” and when variables 
one to three were positive, the diagnosis was “probable steato-
hepatitis.” In the absence of lobular infl ammation and steatosis, 
the diagnosis was “not steatohepatitis”. All patients with alcohol 
consumption >2 doses per day were excluded from the study. 
Chronic hepatitis B and C (HBV and HCV) were excluded using 
serology if alanine aminotransferase values were elevated prior to 
surgery (HCV and HBV infections are rare in Finland ). Hemo-
chromatosis was excluded by histological analysis of liver biop-
sies, and by normal serum ferritin levels in subjects that had an 
elevated serum alanine aminotransferase level. 
 Liver cholesterol content with gas-liquid chromatography 
 Liver total cholesterol content (per 100 mg liver tissue) was 
quantifi ed with gas-liquid chromatography (GLC) on a 50 m 
long capillary column (Ultra 2, Agilent Technologies, Wilming-
ton, DE) using 5  -cholestane as the internal standard ( 25 ). 
 Liver free cholesterol content with NMR spectroscopy 
 Liver samples (approximately 50 mg) were homogenized in 
1.5 ml Eppendorf tubes in NaCl solution (150   l of 150 mM NaCl 
in D 2 O) by pestle. After homogenization, 300   l of CD 3 OD and 
600   l of CDCl 3 were added and samples were mixed vigorously 
using a vortex mixer and sonicated for 15 min (indirect sonica-
tion) in an ice bath. After mixing, the samples were centrifuged 
(5,000  g , 10 min, 4°C) to separate the organic and water phase. 
The lower organic phase was recovered and the aqueous layer 
was extracted again, fi rst with 600   l and then with 300   l CDCl 3 
to standardize the yield. The separated organic layers were com-
bined and evaporated to dryness under a gentle fl ow of dried air. 
Prior to NMR analysis, the extracted lipids were redissolved into 
600   l of CDCl 3 containing 0.03% of tetramethylsilane as a refer-
ence substance. 
 1 H NMR spectra of extracted lipids were recorded on a Bruker 
Avance III HD 600 NMR spectrometer operating at 600.28 MHz 
and equipped with a Prodigy TCI 5 mm cryogenically cooled 
probe head. Standard 1D  1 H NMR spectra were recorded with 
96,000 data points using 32 transients and applying a standard 
Bruker zg pulse sequence. The acquisition time was 5 s and the 
relaxation delay was 15 s. The spectra were measured at 295,000 . 
increased lipid production in the liver. It has also been 
suggested that high LDL cholesterol relates to NASH and 
liver fi brosis ( 11, 12 ), suggesting that the association of 
NASH with serum lipids is not only related to increased 
VLDL synthesis. 
 We investigated the association between serum lipopro-
tein subclasses and NASH. Our hypotheses were that dys-
lipidemia in NASH includes altered lipoprotein subclass 
lipid profi le, and specifi cally that changes in cholesterol 
metabolism associate with liver infl ammation and injury. 
To answer these questions, we investigated serum lipopro-
tein subclasses using NMR spectroscopy ( 13 ) in 116 obese 
individuals with detailed liver histology. The main fi nding 
was that the levels of total lipids and cholesterol in VLDL 
and LDL subclasses were linked to infl ammation and cell 
injury in NASH, but not to simple steatosis. These changes 
were corrected with obesity surgery. 
 MATERIALS AND METHODS 
 Subjects 
 All patients undergoing obesity surgery in Kuopio University 
Hospital are recruited into our ongoing study investigating meta-
bolic consequences of obesity surgery (Kuopio Obesity Surgery 
Study) ( 14, 15 ). The study group included 116 consecutive sub-
jects [age 47.3 ± 8.7 (mean ± SD) years, BMI 45.1 ± 6.1 kg/m 2 , 39 
men and 77 women], who were accepted for the Roux-en-Y gas-
tric bypass (RYGB) operation over the years 2005–2010. Fifty-
nine patients had serum NMR data available also 1 year after the 
surgery. The study protocol was approved by the Ethics Commit-
tee of the Northern Savo Hospital District (54/2005,104/2008, 
and 27/2010), and it was performed in accordance with the Dec-
laration of Helsinki. Written informed consent was obtained 
from the subjects. 
 Laboratory determinations 
 Diabetes was defi ned by WHO’s criteria of diabetes ( 16 ). 
Plasma glucose, insulin, serum total cholesterol, HDL choles-
terol, and triglyceride levels were analyzed as described before 
( 14, 15 ). 
 Serum lipoprotein subclass analysis by NMR spectroscopy 
 Fasting concentrations of lipoprotein subclass particles and 
their main lipid components were analyzed by proton NMR spec-
troscopy in native serum samples ( 13, 17, 18 ). The details of this 
methodology have been described previously ( 13, 19 ), and this 
platform has recently been applied in various large-scale epide-
miological and genetic studies ( 20–22 ). The lipoprotein subclass 
data available are as follows: chylomicrons and largest VLDL par-
ticles (average particle diameter at least 75 nm); fi ve different 
VLDL subclasses: very large VLDL (average particle diameter of 
64.0 nm), large VLDL (53.6 nm), medium VLDL (44.5 nm), 
small VLDL (36.8 nm), and very small VLDL (31.3 nm); IDL 
(28.6 nm); three LDL subclasses: large LDL (25.5 nm), medium 
LDL (23.0 nm), and small LDL (18.7 nm); and four HDL sub-
classes: very large HDL (14.3 nm), large HDL (12.1 nm), me-
dium HDL (10.9 nm), and small HDL (8.7 nm). The following 
components of the lipoprotein particles were quantifi ed: phos-
pholipids, triglycerides, and cholesterol. Due to resolution and 
concentration issues, all of these components are not available 
for every subclass ( 17, 18, 20 ). The VLDL cholesterol concentration 
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(version 2.0.1) ( 29 ). FDR values <0.1 were considered to indicate 
a statistically signifi cant difference. 
 RESULTS 
 Subject characteristics 
 Seventy-six out of the 116 patients had a clearly defi ned 
liver phenotype: 32 had normal liver, 19 had simple steato-
sis, and 25 had NASH ( Table 1 ). Levels of fasting insulin 
and total and LDL cholesterol ( P = 0.006,  P = 0.004, and 
 P = 0.010, Kruskall-Wallis test) differed between study 
groups. Total and LDL cholesterol were higher in indi-
viduals with NASH compared to those with simple steatosis 
( P = 0.002 and  P = 0.007). The results were essentially the 
same if individuals using cholesterol-lowering medication 
(n = 21) were excluded (supplementary Table IV). 
 Serum lipids in relation to steatosis, infl ammation, and 
fi brosis 
 Next, we investigated to determine whether the associa-
tion between NASH and serum lipids is related to steatosis, 
infl ammation, or fi brosis in the liver. To this aim, obese 
patients were divided into four groups based on severity 
of steatosis (steatosis grades: <5%, 5–33%, 33–66%, and 
>66%; supplementary Table II, upper part); into three 
groups based on lobular infl ammation (no infl ammatory 
cells, <2 cells per 200× fi eld, and 2–4 cells per 200× fi eld; 
supplementary Table II, middle part); and into three 
groups based on fi brosis stage (by combining stages 2–4; 
 Data processing.  The free induction decays (FIDs) with 
96,000 data points were zero-fi lled to 256,000 data points and 
multiplied by an exponential window function with a 0.3 Hz line-
broadening. The areas of the known lipid resonances ( 26 ) in the 
spectra were determined using a constrained total-lineshape fi t-
ting approach to enable quantitative analysis of severely overlap-
ping peaks and to increase the quantifi cation accuracy ( 27 ). This 
methodology allowed us to get information on the amounts of 
several lipid components in the extracted samples, e.g., free cho-
lesterol and total triglycerides. The PERCH NMR software was 
used for all the lineshape fi tting analyses. 
 Liver gene expression and genotyping 
 Quantitative real-time PCR was carried out in the Applied Bio-
systems 7500 real-time PCR system using KAPA SYBR FAST qPCR 
Universal Master Mix (Kapa Biosystems, Woburn, MA). Primers 
are available in supplementary Table III. We genotyped rs738409 
SNP of patatin-like phospholipase domain containing 3 ( PNPLA3 ) 
( 28 ) (using the TaqMan SNP genotyping assay (Applied Biosys-
tems) according to the manufacturer’s protocol. 
 Statistical analysis 
 Data are presented as mean ± SD. Differences between the 
study groups were examined with the   2 test (in categorical vari-
ables) and by nonparametric Kruskall-Wallis test (continuous 
variables). Spearman rank correlation was used for correlation 
analysis. General linear model analysis was used for studying the 
independent contributions of variables on liver histology. Anal-
yses were conducted with the SPSS version 19 (IBM SPSS). Mul-
tiple testing of several related lipid phenotypes was corrected 
using false discovery rate (FDR) calculated by the Benjamini-
Hochberg method as implicated in the “p adjust method” in R 
 TABLE 1. Clinical characteristics based on liver phenotype 
Normal Liver (n = 32) Simple Steatosis (n = 19) NASH (n = 25)  P a 
Sex (male/female) 11/21 4/15 10/15 0.404
Age (y) 47.9 ± 9.7 45.8 ± 9.8 46.7 ± 8.0 0.725
Weight (kg) 127.2 ± 19.4 126.2 ± 14.8 132.1 ± 24.5 0.676
BMI (kg/m 2 ) 44.1 ± 6.8 44.8 ± 4.3 44.3 ± 6.9 0.716
Fasting glucose (mmol/l) 6.1 ± 0.9 6.3 ± 1.2 6.5 ± 1.6 0.929
Fasting insulin (mU/l) 14.5 ± 9.0 19.7 ± 10.1 25.4 ± 17.1 b 0.006 
Total cholesterol (mmol/l) 4.23 ± 0.8 3.80 ± 0.9 4.74 ± 1.0 b , c 0.004
LDL cholesterol (mmol/l) 2.48 ± 0.7 2.11 ± 0.8 2.89 ± 1.0 c 0.010
HDL cholesterol (mmol/l) 1.07 ± 0.3 1.02 ± 0.2 1.06 ± 0.4 0.539
Total triglycerides (mmol/l) 1.49 ± 0.7 1.46 ± 0.6 1.74 ± 0.6 0.103
Non-HDL cholesterol (mmol/l) 2.23 ± 0.6 2.02 ± 0.6 2.67 ± 0.8 b , c 0.012
Steatosis grade (n) 8.0 × 10   17 
 <5% 32 0 0
 5–33% 0 15 10
 33–66% 0 2 10
 >66% 0 2 5
Lobular infl ammation (n) 1.2 × 10   15 
None 32 19 0
 <2 Foci per 200× fi eld 0 0 17
 2–4 Foci per 200× fi eld 0 0 8
 >4 Foci per 200× fi eld 0 0 0
Fibrosis (n) 6.6 × 10   11 
 0 32 19 4
 1 0 0 19
 2 0 0 1
 3 0 0 0
 4 0 0 1
 a P value is over all groups. Kruskal-Wallis test for continuous variables and chi-square test for categorical 
variables.
 b Normal liver versus NASH,  P < 0.05.
 c Steatosis versus NASH,  P < 0.05.
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with NASH, but not signifi cantly in those with simple ste-
atosis ( Fig. 1A ). 
 Next, we investigated the association of total lipoprotein 
lipid concentration with steatosis, infl ammation, or fi bro-
sis (detailed results in supplementary Tables V–VII). No 
signifi cant associations were observed between subclass 
lipid concentration and steatosis (FDR > 0.1,  Fig. 1B ), 
while total lipid concentration in all VLDL, IDL, and LDL 
subclasses (excluding very small VLDL) was increased by 
20–80% in relation to infl ammation ( Fig. 1C ) and grade 
1 fi brosis ( Fig. 1D ). Stage 2–4 fi brosis was characterized 
with lower lipoprotein lipid concentrations than grade 1 
( Fig. 1D ). Furthermore, the total lipid concentration of all 
VLDL and LDL particles associated with the NAFLD activ-
ity score [that measures histological injury in NASH com-
bining information about steatosis, infl ammation, and 
liver cell injury ( 24 )] and with ballooning [a histological 
marker of liver cell injury in NASH (FDR < 0.1, data not 
shown)]. The total lipid concentration of HDL subclasses 
was not altered in relation to steatosis or infl ammation, 
but stage 1 fi brosis related to higher HDL lipid concentra-
tion ( Fig. 1D ). 
supplementary Table II, lower part). Steatosis associated 
with higher fasting insulin levels ( P = 0.002), but not with 
serum lipids (supplementary Fig. I). In contrast, lobular 
infl ammation and stage 1 fi brosis associated with total and 
LDL cholesterol ( P = 0.0001–0.022; supplementary Fig. IB, 
C). In addition, individuals with stage 1 fi brosis had higher 
total triglycerides ( P = 0.008) than individuals without any 
sign of fi brosis (supplementary Fig. IC). There was no dif-
ference when comparing individuals without fi brosis to 
those with grades 2–4 fi brosis, suggesting a decline in se-
rum lipids when moving from stage 1 to a more advanced 
stage of fi brosis. 
 VLDL and LDL lipid concentration associates with 
infl ammation, fi brosis, and liver cell injury 
 The serum lipid and lipoprotein analysis was extended 
to a more detailed lipoprotein subclass analysis using 
NMR spectroscopy ( 13, 19 ) ( Fig. 1A ). Total lipid concen-
tration of VLDL (excluding very small VLDL) and me-
dium and small LDL associated with NASH (FDR < 0.1, 
 Table 2 ). More specifi cally, total lipid concentration of 
VLDL and LDL subclasses was increased in individuals 
 Fig.  1. Lipoprotein subclass lipid concentration in individuals divided into groups by liver phenotype divided to those with normal liver 
histology (n = 32), simple steatosis without infl ammation and cell injury (n = 19) and to those with NASH (n = 25) (A), steatosis grade (B), 
lobular infl ammation (C), and fi brosis stage (D). Percentage changes comparing to the group without the pathology (set to 0%) have been 
calculated. Statistical signifi cance over all groups (normal and all degrees of pathology in each panel) are visualized with FDR < 0.05 (*) 
and FDR < 0.01 (#) compared with individuals without the pathology below the horizontal axis in each panel. The color of the symbol in-
dicates subgroup analysis comparing a given group to the group without pathology (gray indicates  P < 0.05, black indicates  P < 0.01 ). 
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LDL subclasses). We also demonstrated that the associa-
tion of lipoprotein cholesterol concentrations with liver 
infl ammation remained signifi cant when adjusted for fast-
ing insulin ( P = 0.012–0.045). 
 VLDL cholesterol correlates with liver total and free 
cholesterol content 
 To explain the link between lipoprotein cholesterol me-
tabolism and liver disease, we analyzed the association be-
tween lipoprotein cholesterol concentrations and liver 
cholesterol content (n = 52). Liver cholesterol content 
measured by GLC correlated with lobular infl ammation 
(r s = 0.393,  P = 0.004), as expected, but not signifi cantly 
with steatosis (r s = 0.258,  P = 0.065) and fi brosis (r s = 
  0.186,  P = 0.221). Interestingly, liver cholesterol content 
also correlated with VLDL cholesterol, but not with LDL 
and HDL cholesterol ( Fig. 2B ). To further study the inter-
action between liver cholesterol metabolism and NASH, 
we measured liver free cholesterol content with NMR in 
the available liver samples (n = 45). First, our observation 
that liver triglyceride content measured with NMR correlated 
 We also evaluated whether the lipid composition (as a 
percentage of individual lipids from total lipids) would 
alter in NASH. There were no differences in the lipid 
composition of any lipoprotein subclass in relation to ste-
atosis and infl ammation, and only small changes in rela-
tion to fi brosis (supplementary Table VIII). 
 VLDL and LDL cholesterol associates with liver 
infl ammation independent of steatosis and serum 
triglycerides 
 The liver cholesterol accumulation has been associated 
with NASH ( 9, 12, 30 ), and our traditional lipid analysis 
supported an association between cholesterol metabolism 
and NASH (supplementary Fig. I). The cholesterol con-
centration of VLDL (except in small VLDL), IDL, and 
LDL associated with infl ammation and fi brosis (FDR < 
0.05; supplementary Fig. II; supplementary Tables V–VII), 
but not with steatosis. Importantly, in multivariate analysis 
the association of VLDL and LDL cholesterol concentra-
tion with liver infl ammation was independent of steatosis 
and serum total triglycerides ( P = 0.024–0.049 for small, 
medium, and large VLDL and for large and medium 
 TABLE 2. Serum lipoprotein subclass data according to liver phenotype 
Normal Liver 
(n = 32)
Simple Steatosis 
(n = 19) NASH (n = 25) P a FDR
Total lipids in (mmol/l)
 Chylomicrons and extremely 
 large VLDL
0.025 ± 0.021 0.036 ± 0.031 0.048 ± 0.026 0.0007 0.0065
 Very large VLDL 0.069 ± 0.050 0.090 ± 0.069 0.129 ± 0.061 0.0004 0.0065
 Large VLDL 0.277 ± 0.153 0.330 ± 0.211 0.456 ± 0.185 0.0017 0.0074
 Medium VLDL 0.566 ± 0.198 0.597 ± 0.266 0.783 ± 0.246 0.0022 0.0077
 Small VLDL 0.629 ± 0.145 0.596 ± 0.159 0.778 ± 0.205 0.0013 0.0065
 Very small VLDL 0.508 ± 0.124 0.462 ± 0.096 0.549 ± 0.172 0.1255 0.1515
 Total IDL 1.033 ± 0.255 0.936 ± 0.237 1.151 ± 0.344 0.0651 0.0872
 Large LDL 1.206 ± 0.301 1.095 ± 0.310 1.409 ± 0.416 0.0154 0.0250
 Medium LDL 0.694 ± 0.181 0.638 ± 0.203 0.844 ± 0.258 0.0095 0.0179
 Small LDL 0.457 ± 0.120 0.433 ± 0.156 0.574 ± 0.184 0.0097 0.0179
 Very large HDL 0.266 ± 0.135 0.267 ± 0.160 0.301 ± 0.193 0.6399 0.6399
 Large HDL 0.463 ± 0.264 0.390 ± 0.249 0.451 ± 0.300 0.3278 0.3585
 Medium HDL 0.844 ± 0.175 0.821 ± 0.107 0.901 ± 0.188 0.2808 0.3170
 Small HDL 1.110 ± 0.090 1.095 ± 0.168 1.167 ± 0.128 0.0781 0.0976
Total cholesterol in (mmol/l)
 Large VLDL 0.062 ± 0.035 0.071 ± 0.046 0.100 ± 0.040 0.0011 0.0065
 Medium VLDL 0.160 ± 0.053 0.159 ± 0.063 0.214 ± 0.066 0.0028 0.0082
 Small VLDL 0.232 ± 0.060 0.207 ± 0.054 0.277 ± 0.082 0.0028 0.0082
 Total IDL 0.633 ± 0.156 0.567 ± 0.148 0.703 ± 0.205 0.0440 0.0616
 Large LDL 0.797 ± 0.213 0.712 ± 0.222 0.937 ± 0.293 0.0157 0.0250
 Medium LDL 0.453 ± 0.131 0.406 ± 0.107 0.558 ± 0.188 0.0096 0.0179
 Small LDL 0.283 ± 0.083 0.260 ± 0.103 0.357 ± 0.127 0.0141 0.0247
 Very large HDL 0.151 ± 0.080 0.161 ± 0.095 0.175 ± 0.093 0.5106 0.5256
 Large HDL 0.217 ± 0.118 0.183 ± 0.130 0.208 ± 0.162 0.2098 0.2448
 Medium HDL 0.415 ± 0.094 0.401 ± 0.063 0.439 ± 0.098 0.3646 0.3867
Triglycerides in (mmol/l)
 Chylomicrons and extremely 
 large VLDL
0.019 ± 0.015 0.027 ± 0.022 0.035 ± 0.019 0.0009 0.0065
 Very large VLDL 0.045 ± 0.032 0.060 ± 0.044 0.084 ± 0.040 0.0004 0.0065
 Large VLDL 0.163 ± 0.089 0.198 ± 0.125 0.269 ± 0.111 0.0019 0.0074
 Medium VLDL 0.292 ± 0.111 0.321 ± 0.156 0.415 ± 0.139 0.0035 0.0094
 Small VLDL 0.253 ± 0.067 0.255 ± 0.087 0.329 ± 0.088 0.0012 0.0065
 Very small VLDL 0.119 ± 0.028 0.112 ± 0.023 0.142 ± 0.040 0.0095 0.0179
 Total IDL 0.120 ± 0.032 0.111 ± 0.020 0.138 ± 0.041 0.0313 0.0457
 Very large HDL 0.010 ± 0.004 0.009 ± 0.004 0.013 ± 0.005 0.0079 0.0179
 Small HDL 0.042 ± 0.010 0.042 ± 0.010 0.048 ± 0.011 0.0673 0.0872
Apolipoproteins (g/l)
 Apolipoprotein A-I 1.367 ± 0.200 1.311 ± 0.186 1.476 ± 0.231 0.0179 0.0272
 Apolipoprotein B 0.860 ± 0.179 0.821 ± 0.189 1.023 ± 0.246 0.0060 0.0150
a Kruskal-Wallis test. FDR with Benjamini-Hochberg method.
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infl ammation, or fi brosis (all  P > 0.3, data not shown). 
Thus, the transcriptional upregulation of the cholesterol 
synthesis genes does not explain the association between 
VLDL cholesterol and NASH. Interestingly, we found that 
X-box binding protein 1 ( XBP1 ) splicing in the liver cor-
related with lobular infl ammation (r s = 0.272,  P = 0.014) 
and ballooning (r s = 0.243,  P = 0.029), but not with steato-
sis (r s = 0.080,  P = 0.479). Because  XBP1 splicing also asso-
ciated with cholesterol concentration of small VLDL, IDL, 
LDL subclasses and medium HDL (r s = 0.220–0.313,  P < 
0.05), endoplasmic reticulum stress could potentially be a 
link between cholesterol metabolism and NASH. 
 Although the  PNPLA3 genotype has been associated 
with liver fat ( 15, 31 ), and also tended to associate with 
steatosis in our study ( P = 0.080,   2 test), there was no as-
sociation of the  PNPLA3 genotype with serum lipids (all 
 P > 0.2, data not shown). 
 Obesity surgery normalizes NASH-related lipoprotein 
abnormalities 
 To determine whether obesity surgery normalizes 
NASH-related lipoprotein abnormalities, we analyzed se-
rum NMR results before and after RYGB. The effect of 
RYGB on total lipid concentration of different lipoprotein 
subclasses is shown in  Fig. 3A (more detailed in supple-
mentary Table XI). The VLDL and LDL lipid accumula-
tions that were associated with NASH ( Fig. 3B ) decreased 
signifi cantly after surgery. In contrast, HDL lipid concen-
tration that was not associated with simple steatosis or 
NASH clearly increased with weight loss. To investigate 
whether obesity surgery corrects NASH-related dyslipid-
emia, we divided patients not using cholesterol lowering 
medication to those without NASH (n = 27) at baseline 
and to those with possible/defi nite NASH (n = 20, for defi -
nition see Materials and Methods) at baseline. The in-
creases in VLDL, IDL, and LDL cholesterol and serum 
triglycerides in individuals with NASH normalized after 
surgery to levels comparable with the levels in individuals 
without NASH (all changes  P < 0.05) ( Table 3 ). 
 DISCUSSION 
 Our study was set to assess whether lipoprotein subclass 
metabolism is linked with NAFLD or NASH. High serum 
VLDL and LDL lipid concentration related to liver infl am-
mation and fi brosis more than to steatosis ( Fig. 1 ). More 
specifi cally, we explored the association of cholesterol me-
tabolism with liver injury in NASH ( 9, 12, 32 ). Both VLDL 
and LDL cholesterol concentrations associated with liver 
infl ammation and fi brosis ( Fig. 2 ), and VLDL subclass 
cholesterol concentrations associated also with liver cho-
lesterol content. This association was independent of ste-
atosis and serum triglycerides ( Fig. 2 and multivariate 
analysis) suggesting an independent link between VLDL 
and LDL cholesterol and NASH. 
 A key fi nding in this study was that high serum VLDL 
and LDL lipid concentration related to lobular infl amma-
tion in the liver independent of steatosis ( Table 2 ,  Fig. 1C , 
with steatosis determined by histology validates our NMR 
methodology (r s = 0.772,  P = 5.4 × 10 
  10 ). Second, free 
cholesterol content measured with NMR correlated with 
liver total cholesterol content measured with GLC (r s = 
0.419,  P = 0.024), but not with steatosis, lobular infl amma-
tion, or fi brosis (supplementary Table IX). Similarly to to-
tal liver cholesterol, liver free cholesterol correlated with 
all VLDL subclasses (r s = 0.315–0.381,  P < 0.005), except 
with small VLDL (r s = 0.279,  P = 0.063), and not with LDL 
and HDL cholesterol ( Fig. 2C ). 
 Because high VLDL cholesterol is linked with increased 
cholesterol synthesis in the liver, we also explored mRNA 
expression of genes regulating cholesterol synthesis 
( CYP51A1 ,  DHCR7 ,  DHCR24 ,  HMGCR ,  LSS ,  SC4MOL , 
 SC5D ,  SREBP1a ,  SREBP1c ,  SREBP2 , and  TM7SF2 ) and up-
take ( LDLR ) in the liver. Although mRNA expression of 
some genes regulating synthesis tended to correlate with 
VLDL and LDL cholesterol subclasses (supplementary 
Table X), we could not show any association between the 
expression of cholesterol synthesis genes and steatosis, 
 Fig.  2. A: Lipoprotein subclass cholesterol concentration in indi-
viduals with NASH compared with those with normal liver histol-
ogy. Percentage changes comparing to the group without the 
pathology (set to 0%) have been calculated and statistical signifi -
cance is shown as in  Fig. 1 . Spearman correlation between lipopro-
tein subclass cholesterol concentration and liver cholesterol 
content (B) and liver free cholesterol content (C) (black bars,  P < 
0.05). 
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previous fi ndings suggesting that nonHDL cholesterol 
(VLDL + LDL) is a biomarker for NASH ( 34 ). 
 One potential link between the VLDL and LDL lipid 
contents and NASH is altered cholesterol metabolism in 
the liver. Accumulation of liver cholesterol has been sug-
gested to be important in the pathophysiology of NASH 
( 9 ). Cellular free cholesterol, but not free fatty acids or 
triglycerides, sensitizes to TNF- and Fas-induced steatohepa-
titis ( 35 ). The possible explanation is that free cholesterol 
and multivariate analysis). We also found a link between 
VLDL and LDL lipid concentration and cell injury in 
NASH, quantifi ed by the NAFLD score and ballooning 
( 24, 33 ). These data give a more detailed view on lipopro-
tein subclass metabolism in NASH than earlier fi ndings 
demonstrating increased VLDL synthesis in steatosis ( 4, 
8 ), leading to the suggestion that high serum VLDL and 
LDL lipid concentrations are also related to the progres-
sion from simple steatosis to NASH. This is in line with 
 Fig.  3. Changes in lipoprotein subclass lipid concentrations (A) in response to RYGB in the whole study group compared with baseline. 
B: Shows the effect of RYBG specifi cally in individuals with NASH by showing the difference between the NASH group and the normal 
group at baseline (squares) and the NASH group after RYGB compared with the normal group at baseline (triangles). The color of the 
symbol indicates subgroup analysis comparing a given group to the group without pathology (A) or to baseline (B) (gray indicates  P < 0.05, 
black indicates  P < 0.01). 
 TABLE 3. Effect of obesity surgery on NASH-related alterations in cholesterol concentration of different 
lipoproteins and serum total triglycerides in patients not using cholesterol lowering medication 
Not NASH (n = 27)
Possible/Defi nite 
NASH (n = 20) P b
Total cholesterol
 Before 4.27 ± 0.9 4.98 ± 0.9 0.009
 After 4.48 ± 1.0 4.43 ± 0.8 0.914
 Change 4.9% 11.0% 0.008
 P value for changea 0.189 0.016
VLDL cholesterol
 Before 0.76 ± 0.2 0.82 ± 0.2 0.237
 After 0.69 ± 0.3 0.63 ± 0.2 0.813
 Change 9.2% 23.2% 0.169
 P value for changea 0.073 3.0 × 105
IDL cholesterol
 Before 0.66 ± 0.2 0.78 ± 0.2 0.023
 After 0.67 ± 0.2 0.64 ± 0.2 0.621
 Change 1.5% 17.9% 0.013
 P value for changea 0.709 0.003
LDL cholesterol
 Before 1.67 ± 0.5 2.04 ± 0.6 0.019
 After 1.65 ± 0.6 1.57 ± 0.5 0.949
 Change 1.2% 23.0% 0.022
 P value for changea 0.752 0.001
HDL cholesterol
 Before 1.18 ± 0.2 1.34 ± 0.3 0.037
 After 1.48 ± 0.3 1.60 ± 0.3 0.085
 Change 25.4% 19.4% 0.111
 P value for changea 3.0 × 106 0.0002
Triglycerides
 Before 1.60 ± 0.5 1.75 ± 0.5 0.143
 After 1.25 ± 0.6 1.16 ± 0.4 0.966
 Change 21.9% 33.7% 0.288
 P value for changea 0.002 2.1 × 105
a Paired samples t-test for within subjects comparison.
b Kruskall-Wallis independent samples test for between groups comparison.
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is cytotoxic and can activate both Fas-independent and 
Fas-triggering mitochondrial dysfunction in macrophages 
( 36 ). Thus, it has been proposed that hepatic accumula-
tion of free cholesterol results in cytotoxicity which medi-
ates transition from steatosis to NASH ( 37 ). It has recently 
been suggested that the cause for cholesterol accumula-
tion in NASH is increased cholesterol synthesis ( 30 ). Our 
gene expression fi ndings in the liver support the sugges-
tion that endoplasmic reticulum stress may be a link be-
tween cholesterol metabolism and NASH. We observed 
that altered splicing of XBP1 related to both NASH and to 
changes in cholesterol metabolism linked with NASH. Ear-
lier, the IRE  /XBP1 pathway has been suggested to regu-
late hepatic lipid homeostasis and its dysregulation has 
been associated with NASH ( 38 ). 
 Although both VLDL and LDL cholesterol associated 
with infl ammation and fi brosis, only VLDL cholesterol cor-
related signifi cantly with the liver cholesterol content in our 
study ( Fig. 2B, C ). This suggests that increased synthesis of 
VLDL particles, rather than decreased release of VLDL 
( 39 ), is the key fi nding in NASH. Although we could not 
link liver cholesterol accumulation, or increased VLDL cho-
lesterol concentrations, to increased expression of genes 
regulating cholesterol metabolism, as recently suggested 
( 30, 40 ), our results support the view that changes in lipo-
protein subclass metabolism in NASH relate to infl amma-
tion and cell injury in NASH ( 8, 9, 30, 40–42 ). 
 Importantly, all NASH-related lipoprotein abnormali-
ties were abolished by obesity surgery ( Fig. 3 ). The de-
crease in serum LDL cholesterol and total triglycerides, 
and the increase HDL cholesterol, in response to RYGB 
has been well-characterized ( 43 ). In this study we demon-
strate that the lipoprotein abnormalities related to NASH 
can be corrected with RYGB, also at a subclass level. We 
assume that this is related to the amelioration of NASH. 
Unfortunately, we had only 11 liver biopsies taken at 1 year 
follow-up. As expected ( 44–46 ), they consistently showed 
improved histology (data not shown). 
 Although the study population was limited to 116 pa-
tients, the detailed histological characterization is more ex-
tensive than in most previous studies ( 9, 11, 12, 30 ). In 
addition, the analysis of serum concentrations of lipopro-
tein subclasses, as opposed to using only standard enzymatic 
methods, was a strength in our study. For example, we could 
not identify the expected association between serum total 
triglycerides and NASH ( Table 1 ), but could clearly demon-
strate that triglyceride levels of all VLDL subclasses had as-
sociation with NASH diagnosis ( Table 2 ). Because of ethical 
diffi culties to obtain liver biopsies in healthy lean individu-
als, we only had biopsies from obese individuals. On the 
other hand, by studying obese individuals, we increased the 
possibility to fi nd subjects with NASH. 
 We conclude that VLDL and LDL subclass lipid concen-
trations are associated with lobular infl ammation and liver 
cell injury in NASH. More specifi cally, our results support 
an independent link between VLDL cholesterol, liver cho-
lesterol, and NASH. Finally, we demonstrated that lipo-
protein subclass abnormalities in NASH can be reversed 
with obesity surgery.  
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 The authors of “Lipoprotein subclass metabolism in nonalcoholic steatohepatitis” ( J. Lipid Res . 2014. 55: 2676–2684) 
have informed the  Journal that the following errors appeared in the following fi gures in their article: 
 Fig. 1 (p. 2679) 
 The symbols on the graphs in  Fig. 1A–D were too small and the symbol colors were unclear. The symbol size is now 
enlarged and the color of the symbols is now visible. 
 Fig. 3 (p. 2682) 
 Two data points on  Fig. 3A , L LDL and M LDL, appeared as white squares and should be gray squares. In  Fig. 3B , sym-
bols for both NASH baseline and NASH post RYGB were presented as squares. However, NASH post RYGB should be 
presented as triangles, as correctly stated in the fi gure legend. These errors have been corrected. Symbols on both graphs 
in  Fig. 3A and B have been enlarged for clarity. These corrections do not affect the interpretations of the results or the 
conclusions of the article. 
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